Why the study?
What is the tolerability of spironolactone in patients with chronic heart failure in routine clinical practice?
What is the tolerability of spironolactone in patients with chronic heart failure in routine clinical practice?
In routine clinical practice, spironolactone is frequently discontinued due to potentially serious side-effects like hyperkalemia and renal dysfunction, highlighting the need for careful monitoring.
AIM: To assess how well heart failure patients tolerate spironolactone in routine clinical practice. DESIGN: Retrospective analysis of 226 patients attending a specialist heart failure clinic. RESULTS: One hundred and thirty of 226 (57.5%) patients tried spironolactone at least once. Forty-four of 130 (33.8%) discontinued spironolactone due to side-effects after a mean of 11.1 months; 59/141 (41.8%) trials of spironolactone resulted in at least one side-effect; therapy was stopped in 30/141 (21.3%) trials due to raised potassium or creatinine. Significant risk factors for raised potassium/creatinine were age and baseline potassium level. CONCLUSIONS: Potentially serious side-effects are common despite appropriate use of spironolactone.
No takes yet. Share an insight, caveat, or question.
Witham et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: